Dr. Ernest Bonner from Global Pharma Labs on CEO Money

Dr. Ernest Bonner
Dir. Of Research – Global Pharma Labs Inc.

Global Pharma Labs Inc is a Regulation A Tier 2 company which is now accepting investors through its SEC qualified initial offering. Investors do not have to be “qualified investors”. capital raised will be used to fund clinical trials on the company’s intended first prescription drug product, OA-sys. OA-sys is a breakthrough treatment for osteoarthritis. Global Pharma Labs Inc.
has several other products in the Pipeline including a breakthrough treatment for weight loss.

Global Pharma Labs Inc’s goal is to develop affordable effective treatments of disease and as we march down this path we also intend to create some new wealth.